RenovoRx, Inc. (NASDAQ:RNXT)
| Market Cap | $45.45M+18.4% |
| Revenue (ttm) | $2.78M+199.1% |
| Net Income | -$13.02M-17.2% |
| EPS | -$0.32+13.7% |
| Shares Out | 48.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 477,326 |
| Open | $1.01 |
| Previous Close | $1.05 |
| Day's Range | $0.94 - $1.03 |
| 52-Week Range | $0.77 - $2.59 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 29, 2027 |
About RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RenovoRx, Inc. Stock Analysis — InsiderScore
RenovoRx, Inc. scored higher than 6% of companies evaluated by InsiderBuying, and ranked 84th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at RenovoRx, Inc. bought $46.5K of stock across 1 purchase in the last 90 days, the largest of them $46.5K.
The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating RNXT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 29, 2027Earnings report
$RNXT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RNXT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RNXT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RNXT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RNXT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RNXT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RNXT
| VTIVanguard Morningstar Total Stock Market ETF | $1.24M |
| VXFVanguard Extended Market ETF | $604.54K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RNXT’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-6.5 since Nov 17Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
